Annovis Bio Inc (ANVS)

$ANVS at 40% enrollment in late January and 75% enrollment in late March, I project we are fully enrolled by late May, early June. Add 6 months to that for database lock=January, then 6-8 weeks for analysis, and we have data read out in March 2027. Do we have enough cash till then? I hope so. Next cash raise won’t be till after 6 symptomatic AD data when pps should be higher.

$ANVS $NVDA is up $400,000 million today on no real news; meanwhile the entire market cap of a potentially effective treatment for Alzheimer's is less than $100 million... interesting market we have here...

$ANVS loser

$ANVS Director Michael B. Hoffman acquired 713,800 shares at about $2.10, boosting his holding by 27.72% to 3,288,539 shares, a significant insider purchase signaling confidence.

$ANVS Going to be a said day for some when it gets bought out but I have more than has been sold today so won’t be me

$ANVS as I’ve said before, Maria is going to prison.

$ANVS still believe Maria has the magic, but so many old guards have left, i dont fault them, money can be better used elsewhere especially with AI revolution going on, but keep 5 percent here, it will be a good investment 12 month down the road.

$ANVS get back to 2 today

$ANVS https://healthunlocked.com/cure-parkinsons/posts/152697914/annovis-bio-inc.-announces-progress-in-alzheimers-and-parkinsons-trials

This $ANVS post is likely relevant for the many former CFOs of Annovis Bio #jeffreymcgroarty #henryhagopian #williamfricker #andrewwalsh and #markguerin as well as any contractors who have been openly berated during their time serving the company. This includes any clinical research organizations who were screamed at and blamed for what Annovis Bio states happened: “To recap, here is what happened in our Phase 2/3 Alzheimer’s disease (AD) study: during post-trial analysis, we identified that a significant portion (about 40%) of participants enrolled did not meet diagnostic criteria for AD. This meant that many people were placed into studies that could not help them.” Yet it is CEO Dr. Maccecchini who continuously self-proclaims that she is “really good at development R&D, because that’s my background”. As such, how is it possible for Dr. Maccecchini to feign outrage regarding the outcome of her own study which she designed??? "Annovis CEO Maria Maccecchini says the suspect clinical trial locations in the study of buntanetap offered cash payments and generous spreads of food and beverages to entice volunteers. Many people, she adds, pretended to suffer from cognitive impairment to join the trial, for example by intentionally drawing a clock incorrectly. Maccecchini adds that the participants whose data had to be tossed out included many grandmothers who saw a chance to make thousands of dollars a year by simultaneously joining multiple trials for which they did not qualify.” These are well-known and long-established issues in the industry and if Dr. Maccecchini was “really good at development R&D, because that’s my background” then she would have taken measures to safeguard against this … if she had wanted to. A muddled study prolongs her story … and, the collection of retail investors’ hard-earned money, IMO. Dr. Maccecchini’s interests are neither aligned with retail investors or patients and their families, IMO. Dr. Maccecchini has never mentioned to me her personal interest in helping patients. Instead, she tells me she promises to "make every employee a millionaire”? 🥕 Is this her real focus? 🥕🥕🥕🥕🥕 Has this promise been realized by any of Dr. Maccecchini’s former financial officers/CFOs? Based on observations, those who have worked for or with Dr. Maccecchini have been harmed. This includes contract breaches and the sullying of reputation #tonyrusso #nicjohnson #russopartners based on both written and oral evidence. The referenced post (linked) by “mattil” was responded to by “kgw567,” which can be read on the right side of the attached image: “She (ForestFoxes) seems to be a very nice person, however …” This is a stark contrast from the same commentator, kgw567, who previously attacked me by stating, “Don’t Fuck With Me, I Guarantee you ain’t in the same league and you’re fucking with the wrong person,” (see middle section of the attached image 1). kgw567 appears coached by Dr. Maccecchini, as it reflects how the CEO handles situations when bullying is no longer effective. The CEO's comments, “It is better to disarm him than to fight him,” referring to #AdamFeuerstein. On some days, the CEO seems to have spent more time communicating directly with retail investors than on her “scientific” work and/or running her company. Is this what Annovis Bio investors want? Dr. Maccecchini has directed me in writing to go after specific authors focused in this field. Furthermore, she has written me that such efforts would be supported by her Director of Strategic Communications. Again, is this what patients or investors want in a CEO? Why is Dr. Maccecchini so focused on social media instead of the actual work at hand, which is obtaining funding via entities who specialize in this field and are fully capable of discerning the value of her drug’s valuable data? Unless her data is NOT valuable and NEVER has been 🚩 Annovis Bio’s former CFOs, PR teams, website builders, clinical research organizations (CROs), etc., whose reputation she has damaged based on the facts that I have come across, should be interested in what kgw567 outlined, stating, “Someone posting on here could be in some deep shit!” (see middle section of image 1). IMO ➡️ this person is CEO Maccecchini 👈 🚩 ”Defamation of character refers to a false statement presented as fact that injures an individual’s reputation, and it can take the form of slander (spoken) or libel (written).” as mentioned by kgw567 (middle panel of image 1). #jeffreymcgroarty #henryhagopian #williamfricker #andrewwalsh #markguerin